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Objective: The reduction of oral prednisone use by mometasone furoate (MF) delivered by
HFA-227 metered dose inhaler (MDI) was examined in oral corticosteroid (OCS)-dependent
patients with severe persistent asthma.
Methods: A 3-month, double-blind, placebo-controlled clinical trial (n ¼ 123), followed
by a 9-month open-label phase (n ¼ 120). The study was conducted at 26 medical centers
in the United States. Patients were randomized to treatment with MF-MDI 400 or 800 mg
twice-daily (bid) doses, or placebo in the double-blind trial. All patients received MF in the
open-label phase.
Results: At the endpoint of the double-blind trial, MF-MDI 400 and 800 mg bid reduced the
daily OCS dose by 39.4% and 31.1%, respectively, while placebo increased the OCS dose by
107.2% (Po0.01). The OCS requirement was reduced by 50% or more in 63% and 60% of
patients treated with MF-MDI 400 and 800 mg bid, respectively, compared with 14% of
patients receiving placebo. After 12 weeks, despite prednisone reductions, pulmonary
function, asthma symptoms, albuterol use, nocturnal awakenings, and physician-evaluatedElsevier Ltd. All rights reserved.
465 5400; fax: +1 516 465 5454.
(J.P. Karpel).
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compared with placebo. Further reductions in OCS requirements were achieved with
long-term MF-MDI treatment in the open-label phase, with an overall 67% reduction in
prednisone usage and 51% of patients completely eliminating prednisone usage by the
1-year time point.
Conclusion: MF delivered by HFA-227 MDI signiﬁcantly reduces daily OCS use compared
with placebo and facilitates elimination of OCS use in patients with severe persistent
asthma.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Inhaled corticosteroids (ICS) have largely replaced oral
corticosteroids (OCS) in the management of severe persis-
tent asthma. The National Asthma Education and Prevention
Program’s (NAEPP) Expert Panel recommends high doses
of inhaled corticosteroids, with the addition of long-
acting bronchodilators if needed, to control severe persis-
tent asthma symptoms in patients 45 years of age.1,2
Although, ICS therapy provides effective long-term control
of asthma symptoms1–4 with a reduced risk of adverse
systemic affects compared with OCS, a number of patients
are perceived to be OCS-dependent or experience recurrent
exacerbations requiring frequent bursts of OCS. When
treating severe persistent asthma the challenge is to
eliminate or reduce OCS requirements for these patients
while maintaining pulmonary function and quality of life
(QoL).
Due to the adverse systemic effects often related to OCS
use, such as adrenal and immune suppression, Cushing’s
syndrome, growth retardation, and bone mineral loss,5
there has been great interest in ﬁnding effective treatment
alternatives for severe persistent asthma with a reduced risk
of adverse systemic effects. It has been previously demon-
strated that ICS can be effective in eliminating OCS use in a
signiﬁcant number of OCS-dependent patients with severe
persistent asthma.6–9 Speciﬁcally, we have previously
reported that mometasone furoate (MF) administered by
dry powder inhaler is effective in reducing OCS require-
ments, improving pulmonary function and asthma symptom
scores, while reducing albuterol use, and improving QoL.9
MF is a highly potent topical steroid currently available in
dermatologic and nasal preparations. In vitro studies have
shown MF to be one of the more potent corticosteroids in
inhibiting cytokine production, histamine release, and
eosinophil survival.10,11 Two inhaled preparations of MF
have been evaluated in the treatment of asthma. One is for
delivery by dry powder inhaler (DPI) and one is for delivery
by metered dose inhaler (MDI) with HFA-227 as a propellant.
The DPI formulation has been approved for use in over 42
countries, including the United States. Both inhalers have
minimal effects on the hypothalamic–pituitary–adrenal
(HPA) axis.12 MF-MDI was found to have negligible effects
on the HPA axis in adult patients treated with doses as high
as 1200 mg daily.12 MF-DPI is highly efﬁcacious in patients
with all severities of persistent asthma.13–17
The purpose of this study is to examine the effect of MF-
MDI (HFA-227) on reducing the OCS requirements of patients
with severe persistent asthma.Methods
Patients
Male and female patients X12 years of age with OCS-
dependent severe persistent asthma, were recruited at 26
medical centers in the United States. For eligibility,
participants in the study were required to have had severe
persistent asthma for at least 12 months prior to enrollment
and to have required daily or alternate-day OCS for at least
5 of the 6 months prior to study enrollment. Eligible patients
also were required to have an forced expiratory volume in
1 s (FEV1) of 40–85% of predicted value and documentation
of a 12% or greater increase in FEV1 with an absolute volume
increase of 200mL or greater in response to b2-agonist or
glucocorticoid treatment within the previous 12 months.
Patients on ICS therapy had to be on a stable dose regimen
within the following dose ranges: ﬂunisolide 1000–2000 mg
daily; triamcinolone acetonide 600–1600 mg daily; beclo-
methasone dipropionate 252–840 mg daily; ﬂuticasone pro-
pionate 440–880 mg daily; and budesonide, 400–800 mg daily.
A minimum effective prednisone dose was established for
each patient. This was determined through source docu-
ments verifying that attempts at OCS dose reduction in
previous 6 months resulted in clinical deterioration or
reduced lung function. If documentation was not available,
the investigator reduced the OCS dose in step-wise fashion
during a prescreening period of up to 2 months, until
pulmonary function decreased. The patients were then
returned to their previous OCS dose. This minimum effective
dosage of OCS had to be stable in the 2 weeks prior to
screening and through the 2-week run-in period, and in the
range of 5–30mg daily or 10–60mg every other day.
Patients were excluded for any of the following reasons:
immunotherapy (unless on a stable maintenance regimen),
treatment with methotrexate, cyclosporine, gold, or other
cytotoxic agents within the previous 3 months, life-
threatening asthma, or evidence of emphysema, bronch-
iectasis, or cystic ﬁbrosis. No patients had been or were
being treated with omalizumab (anti-IgE antibody) prior to
the study. Institutional review boards representing each
center approved the protocol, and written informed consent
was obtained from each patient before participation.Study design
An initial 3-month, parallel, double-blind, randomized,
placebo-controlled phase comparing MF-MDI (400 and
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open-label treatment phase in which all patients took MF-
MDI. At randomization, the usual prescribed ICS was
discontinued, and patients were randomized to receive
either MF-MDI 400 mg bid, MF-MDI 800 mg bid, or placebo.
Patients taking theophylline, nebulized or oral b2-agonists,
salmeterol, cromolyn, nedocromil, or anticholinergics were
to continue these throughout the study. Use of leukotriene
modiﬁers was prohibited during the study. Throughout the
study, morning (AM) and evening (PM) peak expiratory ﬂow
rate (PEF), asthma symptoms, number of albuterol inhala-
tions, adverse events, and medication use were documented
on daily diary cards.
Following randomization, visits occurred at Day 4, Week 1,
and weekly thereafter until the double-blind treatment
phase ended. Patients were evaluated at each visit to
determine their eligibility for prednisone dose reduction.
The dose was reduced if all of the following criteria were
met: (1) FEV1 was within 20% of baseline; (2) FEV1 wasX40%
of the predicted value; (3) AM PEF was within 20% of mean
baseline; (4) albuterol use had not increased more than 4
puffs above baseline; (5) nocturnal awakenings had not
increased to42 above baseline; (6) a prednisone burst had
not been used in the previous 7 days. The dose of prednisone
was reduced in 5mg steps between 30 and 10mg, in 2.5mg
steps between 10 and 5mg, and in 1.0–2.25mg steps
between 5 and 0mg. Treatment failure as a result of asthma
worsening was deﬁned as having occurred under the
following conditions: (1) an asthma exacerbation leading
to hospitalization; (2) signiﬁcant increases, or an addition
of, any asthma medication except inhaled albuterol or
prednisone to control symptoms; and (3) requirement for a
second burst of prednisone to treat worsening symptoms.
For patients with asthma exacerbations, a prednisone burst
of up to 60mg per day, tapered over a 2-week period to a
dose 2.5mg above the pre-burst daily prednisone dosage
was allowed. If a second prednisone burst was required,
patients were to be discontinued from this phase of the
study but were eligible to enter the 9-month open-label
phase.
Patients completing the double-blind treatment phase, or
discontinuing early for reasons other than adverse events or
noncompliance, were eligible for the open-label phase.
Visits were scheduled weekly for the ﬁrst 4 visits and at
4-week intervals thereafter until the ﬁnal visit at Week 40.
In the open-label phase, patients were initially given MF-MDI
800 mg bid, and the dose could be tapered to as low as 400 mg
bid if the patient had completely eliminated prednisone for
a period of 4 weeks. Patients requiring a prednisone burst
during this phase had the MF-MDI dose increased to 800 mg
bid, and further dose reductions were not attempted for at
least 2 months after the prednisone burst.Efﬁcacy measurements
The primary outcome measure was the percent change in
daily prednisone requirement from baseline to end of study
for the double-blind treatment phase. Other outcome
measures included spirometric measurements for FEV1,
forced vital capacity (FVC), and forced expiratory ﬂow rate
between 25% and 75% of vital capacity (FEF25%–75%), AM andPM PEF, rescue albuterol use, asthma symptom scores,
number of nocturnal awakenings caused by asthma that
required albuterol use, and general and asthma-speciﬁc QoL
measurements. The highest FEV1 from 3 measurements was
recorded. The PEF recorded was the highest of triplicate
measurements made with a Personal Bests peak ﬂow meter.
Symptom severity for wheezing, difﬁculty breathing, and
cough was rated by the patient on a 4-point scale (0 ¼ none,
1 ¼ noticeable, 2 ¼ annoying, 3 ¼ very uncomfortable). For
PEF and asthma symptoms, the average value for the 7 days
preceding the baseline visit and all subsequent weeks was
analyzed. The investigator assessed response to therapy at
each weekly visit on a 5-point scale (1 ¼ much improved,
2 ¼ improved, 3 ¼ no change, 4 ¼ worse, or 5 ¼ much
worse) compared with the symptoms at baseline. QoL was
measured using the acute form of the SF-3618 to determine
health-related quality of life (HRQOL) and an asthma-
speciﬁc questionnaire, the AQLQ.19 Using the previous week
for reference, QoL questionnaires were administered in the
clinic at baseline, at endpoint of the double-blind treatment
phase, and after 3 months in the open-label phase.
Safety assessments
All patients were monitored for adverse events and changes
in physical ﬁndings, vital signs, hematological and blood
chemistry proﬁles, and electrocardiographic proﬁles. The
severity of reported adverse events and their relationship to
treatment was assessed. Mouth and throat cultures were
taken if oral candidiasis was evident on physical examina-
tion.
Cortisol response to cosyntropin stimulation
The response of plasma cortisol to cosyntropin injection was
measured at 11 centers at screening and Week 12 of the
blinded phase (n ¼ 39), and at the end of the open-label
phase (n ¼ 30). A prestimulation plasma sample was taken
at 8 AM (71 h), followed by intravenous administration of
cosyntropin 0.25mg. A post-stimulation plasma sample was
taken after 30min. Plasma cortisol was quantiﬁed using high
performance liquid chromatography.
Plasma mometasone furoate concentrations
At the same centers that tested cortisol responses, plasma
MF concentrations were determined at the last study visit
(Week 12) of the blinded phase, using a validated high-
performance liquid chromatography assay with tandem mass
spectrometry detection.20 The plasma samples were ob-
tained both prior to and 30min after the ﬁnal dose of MF-
MDI. The limit of quantiﬁcation of the assay was 48.5 pg/mL
of MF.
Statistical analysis
A sample size of 40 patients per treatment group was chosen
to detect, with 85% power and a 5% signiﬁcance level, a
clinically relevant (X40%) pairwise difference in the mean
percentage change from baseline to endpoint in daily
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group and the placebo group.6 Endpoint was deﬁned as the
last observation obtained for an individual during the
treatment period. The primary efﬁcacy analysis was based
on all randomized patients who received at least 1 dose of
study medication and who had postbaseline data (intent-to-
treat principle). In addition to the analysis at endpoint,
pairwise comparisons among the 3 treatment groups were
made with respect to the percentage change from baseline
in daily prednisone requirement for each scheduled visit. All
other efﬁcacy variables were analyzed at each time point.
Both primary and secondary endpoints were analyzed by
using a 2-way analysis of variance (ANOVA). Pairwise
comparisons were based on least square means from the
ANOVA using a 5% level of signiﬁcance. In addition,
the baseline values of oral prednisone requirement and
the consistency of results across centers were assessed. All
values are reported as the mean7SEM.
Results
Patient characteristics
A total of 123 patients were randomized to 3 groups. The
demographic data and asthma-related characteristics were
similar among the groups (Table 1). Almost all of the
patients (88%) were taking ICS at the time of entry into the
study, and the distribution of different formulations and
doses were comparable among the groups (Table 1). At
baseline, the mean daily prednisone dose and secondary
measures of pulmonary function showed no signiﬁcant group
differences (Table 2).
Double-blind, placebo controlled treatment phase
Eighty-three (67%) of the 123 patients enrolled, completed
the entire 3-month phase of the study. Twenty-two patients
taking placebo discontinued before 3 months because of
treatment failure (worsened asthma), compared with 9
patients receiving MF-MDI 400 mg bid and 5 patients
receiving MF-MDI 800 mg bid. There was 1 death in the MF-
MDI 400 mg bid group, due to respiratory insufﬁciency and
pneumonia, considered by the investigator to be unrelated
to treatment. No patients were lost to follow-up or were
noncompliant in this double-blind phase of the study.
Kaplan–Meier analysis of the probability of remaining in
the study (i.e., time to treatment failure because of
worsening asthma) found that median time to asthma
worsening was 63 days in the placebo group, while median
time to worsening could not be calculated for the MF-MDI
groups because478% in these groups did not worsen by the
end of the treatment period (data not shown). Log-rank
analysis showed that time to asthma worsening was
signiﬁcantly longer in the MF-MDI groups compared with
the placebo group (Po0:01).
Oral prednisone use
From baseline to endpoint, the mean daily oral prednisone
dose decreased by 39.4% in the MF-MDI 400 mg bid group, andby 31.1% in the MF-MDI 800 mg bid group, compared with an
increase of 107.2% the placebo group (Fig. 1A; Po0:01 vs.
placebo) At endpoint of the double-blind phase, 36% of the
patients in the MF-MDI 400 mg bid group and 28% of the
patients in the MF-MDI 800 mg bid group were able to
completely eliminate oral prednisone use, while one patient
(3%) in the placebo group completely eliminated prednisone
(Fig. 1B). Additionally, 60% of the MF-MDI 400 mg bid group
and 63% of the MF-MDI 800 mg bid group decreased the daily
prednisone dose by 50% or more, while only 14% of the
placebo group achieved the same reduction. In fact, 58% of
patients treated with placebo increased their daily pre-
dnisone use from baseline to endpoint.Pulmonary function
Both doses of MF-MDI consistently increased pulmonary
function (Table 2 and Fig. 2) when compared with placebo.
Despite substantial reductions in oral prednisone use, FEV1
was signiﬁcantly improved at endpoint for both MF-MDI
dosage groups compared with placebo patients, who had
increased prednisone use (Po0:01). FEF25%–75% and AM PEF
both showed signiﬁcant differences at endpoint for MF-MDI
400 mg bid compared with placebo, and these measures were
marginally signiﬁcant for MF-MDI 800 mg bid (Po0:08 and
Po0:07, respectively) compared with placebo.Asthma symptoms and rescue medication use
Other secondary measures showed that MF-MDI maintained
or improved asthma symptoms relative to placebo at
endpoint (Table 3). Despite the substantial reduction of
prednisone use in the MF-MDI groups, AM wheezing scores
were signiﬁcantly improved compared with placebo at
endpoint for both MF-MDI doses (Po0:01). The AM difﬁculty
breathing score also signiﬁcantly improved when compared
with placebo (P ¼ 0:02) for MF-MDI 800 mg bid, and proved
marginally signiﬁcant (P ¼ 0:07) for MF-MDI 400 mg bid. In
addition, the number of nocturnal awakenings requiring the
use of albuterol, daily use of albuterol, and physician’s
evaluation of response to therapy signiﬁcantly improved
(Po0:01) for both doses of MF-MDI compared with placebo
(Table 3).Health-related quality of life
Ninety-three percent of the patients enrolled in the study
completed questionnaires at baseline and at the double-
blind trial endpoint. At endpoint, there were no signiﬁcant
differences between groups in the change from baseline for
any of the SF-36 HRQOL domain scores, although both of the
MF-MDI groups tended toward improvement relative to
placebo (data not shown). For the AQLQ asthma-speciﬁc
questionnaire, only the MF-MDI 800 mg bid group showed
signiﬁcantly greater (Pp0.05) improvement in total score
(breathlessness, mood, social impact, asthma concerns) and
psychosocial impact than the placebo group (Table 3).
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Table 1 Summary of demographics and asthma-related characteristics.
Placebo MF-MDI (400 mg bid) MF-MDI (800 mg bid)
Demographics
Number of patients 38 42 43
Male/female 18/20 17/25 17/26
Caucasian/African-American/other 31/4/3 34/3/5 32/7/4
Mean age in years (range) 58 (13–80) 52 (13–83) 50 (13–77)
Body weight in kg (range) 81.2 (51.3–140.6) 83.1 (46.7–131.5) 84.1 (53.5–138.3)
Asthma-related characteristics
Mean years with asthma (range) 21 (2–75) 23 (2–61) 23 (3–62)
FEV1: Mean % predicted (range) 61 (34–83) 61 (40–86) 58 (39–83)
Previous inhaled corticosteroids
Number of patients (median mg/day)
Beclomethasone dipropionate 8 (336) 8 (420) 5 (336)
Budesonide 0 4 (800) 0
Flunisolide 4 (1 500) 5 (1 500) 2 (1 750)
Fluticasone propionate 17 (880) 15 (880) 19 (880)
Triamcinolone acetonide 5 (1 000) 8 (800) 8 (1 200)
Number of patients taking theophylline 21 23 23
Table 2 Summary of baseline and change at endpoint data for efﬁcacy parameters for all patients enrolled in the double-
blind phase.
Placebo (n ¼ 38) MF-MDI (400 mg bid)
(n ¼ 42)
MF-MDI (800 mg bid)
(n ¼ 43)
Daily oral prednisone dose (mg)
Baseline 10.0071.14 12.3771.07 13.0271.01
Change at endpoint +9.02 2.65 5.03
Mean change from baseline +107.2% 39.4% 31.1%
Pulmonary function
FEV1 (L)
Baseline 1.7170.12 1.7970.11 1.7170.10
Change at endpoint 0.1770.07 +0.0870.07 +0.0870.06
FVC (L)
Baseline 2.5870.16 2.7270.15 2.6470.14
Change at endpoint 0.1370.09 +0.0870.09 +0.0570.08
FEF25–75% (L/s)
Baseline 1.1570.13 1.1270.12 1.1670.12
Change at endpoint 0.1270.1 +0.1670.09y +0.0970.08
AM PEFR (L/min)
Baseline 297718 303717 292716
Change at endpoint 3714 +20713 +27712
Number (%) of subjects with clinical asthma exacerbations 18 (47) 7 (17) 8 (19)
Mean values or mean7SEM are indicated for each group.
Signiﬁcantly different from placebo (Po0.01).
ySigniﬁcantly different from placebo (P ¼ 0:02); bid, twice daily.
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Patient characteristics
All 120 patients enrolled in the open-label study received at
least one dose of MF-MDI and were evaluated for safety.Eighty-ﬁve percent (n ¼ 102) of the patients completed the
full study. Three patients were discontinued for an adverse
event, 6 discontinued due to treatment failure, 6 did not
wish to continue, 1 was lost to follow-up, and 1 was
discontinued for noncompliance.
ARTICLE IN PRESS
En
dp
oi
nt
(A)
at
ie
nt
s
40
50
60
Treatment Duration (weeks)
0 2 10 12
M
ea
n 
Pe
rc
en
t C
ha
ng
e
-100
-50
0
50
100
150 Placebo
MF-MDI 800 µg bid
MF-MDI 400 µg bid
*
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
Placebo
MF-MDI 400 µg bid
MF-MDI 800 µg bid
4 6 8
Inhaled mometasone furoate reduces oral prednisone usage 633Oral prednisone use and pulmonary function
At endpoint of the open-label phase, there was an overall
67% reduction in prednisone dose compared with that at
baseline before randomization. For those receiving placebo,
MF-MDI 400 mg bid, and MF-MDI 800 mg bid during the double-
blind treatment, oral prednisone was reduced at the
endpoint of the open-label phase by 74%, 69%, and 72%,
respectively. From the time of randomization to the
endpoint of the open-label study, overall, 51% of 120
patients completely eliminated prednisone. Oral prednisone
requirement was completely eliminated for 47%, 56%, and
49%, respectively, of patients who had previously received
placebo, MF-MDI 400 mg, and MF-MDI 800 mg bid during the
double-blind phase. For the 86 patients who completed
the entire 12 months of the study with evaluable data at the
ﬁnal Week 52 visit, 71% completely eliminated prednisone.
Of patients treated with placebo in the double-blind phase,
a substantial proportion (32%) decreased the dose of MF-MDI
from 800 to 400 mg bid during the open-label phase. Despite
the additional reductions in oral prednisone use, improve-
ments in pulmonary function (FEV1 and AM PEF) achieved
during the double-blind phase were maintained during the
open-label phase.(B)
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Figure 1 Effects of MF-MDI on percent change in oral
prednisone requirement. (A) The mean7SEM of the individual
percent changes are shown over the 12 weeks and at endpoint
of the double-blind phase for the placebo and MF-treated
groups. (*Po0.05, **Pp0.01 compared with placebo). (B)
Percent of those patients who increased or decreased the
required prednisone dose at the endpoint of the double-blind
phase.Safety assessment
Double-blind treatment phase
MF-MDI was well tolerated, with no unusual or unexpected
adverse events reported. The majority of adverse events
were considered by investigators to be unrelated to
treatment. Most adverse events were mild to moderate in
severity. Eight patients reported serious AEs (SAEs); 2 in the
MF-MDI 400 mg bid group (pneumonia for both), 4 in the MF-
MDI 800 mg bid group (adrenal insufﬁciency, intestinal
perforation, diverticulitis, and prostatic cancer) and 2 in
the placebo group (atrial ﬁbrillation and coronary artery
disorder). The 3 patients in the MF-MDI 800 mg bid group with
intestinal perforation, diverticulitis, and prostatic cancer
and the placebo patient with atrial ﬁbrillation were
discontinued from the study. All SAEs were considered by
the investigator to be unrelated to treatment. One patient
in the MF-MDI 400 mg bid group died during the course of the
study (due to respiratory insufﬁciency and pneumonia), and
this was considered unrelated to study treatment. Treat-
ment-related oral candidiasis was observed in 26% and 40%
of the patients in the MF-MDI 400 and 800 mg bid groups,
respectively, and in 8% of the placebo group, none of whom
discontinued treatment (Table 4). Dysphonia was reported
by 2% and 7% of patients receiving MF-MDI 400 and 800 mg
bid, respectively, and in 3% of the placebo group.
Treatment-emergent adverse events related to predni-
sone withdrawal (e.g., musculoskeletal pain, arthralgia,
fatigue, and myalgia) were reported by 45% of patients in
the MF-MDI 400 mg bid group, 40% of patients in the MF-MDI
800 mg bid group, and 13% of patients in the placebo group.
This ﬁnding is expected because signiﬁcantly more patients
in the MF-MDI groups reduced or eliminated prednisone use
than did patients in the placebo group. No clinically relevant
changes in vital signs, physical examinations, EKGs, or
clinical laboratory tests were associated with treatment.At screening and on Week 12, there were no signiﬁcant
differences in precosyntropin (screening: 6.87, 6.11,
4.70 mg/dL and Week 12: 5.14, 7.15, 5.88 mg/dL for placebo,
MF-MDI 400 mg bid, and MF-MDI 800 mg bid, respectively) or
postcosyntropin (screening: 15.75, 11.03, 11.91 mg/dL and
Week 12: 12.57, 15.32, 14.90 mg/dL for placebo, MF-MDI
400 mg bid, and MF-MDI 800 mg bid, respectively) cortisol
concentrations among the groups. The percentage of
patients treated with MF-MDI (400 or 800 mg bid) with
morning plasma cortisol concentrations of less than 5mg/dL
decreased from 71% (15/21) at screening to 38% (8/21) on
Week 12. At screening, the placebo group had 56% (5/9) of
patients with abnormal precosyntropin concentrations, and
this decreased slightly to 44% (4/9) on Week 12. The
percentage of abnormal responders to cosyntropin (post-
cosyntropin minus precosyntropin cortisol levels of o7 mg/
dL) decreased from 67% (14/21) at screening to 38% (8/21)
on Week 12 for MF-MDI (400 or 800 mg bid) treated patients.
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cosyntropin in the placebo group went from 56% (5/9) at
screening to 67% (6/9) on Week 12.Treatment Duration (weeks)
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Figure 2 Effects of MF-MDI on pulmonary function in the
double-blind phase. The effects of MF-MDI on mean change
(7SEM) in FEV1 from baseline are shown over 12 weeks and at
endpoint for the placebo and MF-treated groups. (*Po0.05,
**Pp0.01 compared with placebo).
Table 3 Summary of patient self-reports and HRQOL.
Placebo (n ¼ 38) MF-M
Patient self-reports
AM wheezing score
Baseline 0.6970.13 0.847
Change at endpoint +0.2270.16 0.2
AM difﬁculty breathing score
Baseline 0.8570.13 1.077
Change at endpoint +0.2270.17 0.1
AM cough score
Baseline 0.4870.11 0.327
Change at endpoint +0.2170.15 +0.13
Number of awakenings for
Albuterol (per night)
Baseline 0.2870.12 0.527
Change at endpoint +0.4070.13 0.1
Albuterol use (inhalations/day)
Baseline 3.9070.61 5.457
Change at endpoint +1.9370.61 0.6
Physician-evaluated response to therapy
Mean score at endpoint 3.86 2.64
Asthma-speciﬁc score (mean change from baseline)
Total score 0.3 0.4
Physical symptoms 0.2 0.2
Psychosocial impact 0.2 0.6
Signiﬁcantly different from placebo (Po0.01).
ySigniﬁcantly different from placebo (Pp0.05); bid, twice daily.At Week 12, MF concentrations were examined in pre- and
postdose plasma samples at selected centers. In the MF-MDI
400 mg bid treatment group, MF was detected (limit of
quantitation ¼ 48.5 pg/mL) in only 4 of 16 predose samples
(range 48.5–96.1 pg/mL) and in 13 of 15 postdose samples
(49.0–130 pg/mL). In the MF-MDI 800 mg bid treatment
group, MF was detected in 9 of 16 predose samples (range
59.7–118 pg/mL) and in 13 of 15 postdose samples
(59.4–154 pg/mL). MF was not detected in plasma specimens
from the placebo group.
Open-label phase
There was no indication of an increase in incidence of
clinically meaningful adverse events with prolonged treat-
ment. Oral candidiasis and dysphonia were the most
frequently reported treatment-related adverse events dur-
ing the open-label phase (data not shown). Oral candidiasis
was reported in 28% of the patients, one of whom
discontinued treatment. During the last month of treat-
ment, the incidence of oral candidiasis decreased to 6%.
Fourteen patients reported SAEs in the 9-month phase of the
study; none were considered treatment-related. One pa-
tient died during the 9-month phase of the study due to
myocardial infarction and septic shock; this was judged
unrelated to treatment.
Adverse events associated with prednisone withdrawal
were experienced in 38% of the patients. The eventsDI (400mg bid) (n ¼ 42) MF-MDI (800 mg bid) (n ¼ 43)
0.12 0.8070.11
970.15 0.3770.14
0.13 0.7770.12
670.16 0.2470.15y
0.11 0.5570.10
70.14 0.1070.13
0.11 0.4870.11
370.12 0.1370.11
0.58 5.1770.54
170.57 0.8570.54
2.38
0.9y
0.3
0.7y
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Table 4 Incidence of patients reporting adverse events during the double-blind phase, which were judged by the
investigator to be possibly or probably associated with treatment.
Placebo (n ¼ 38) MF-MDI (400 mg bid) (n ¼ 42) MF-MDI (800 mg bid) (n ¼ 43)
Number of patients with any event 10 (26%) 17 (40%) 24 (56%)
Dry mouth 2 (5%) 0 1 (2%)
Aggravated allergy 0 0 2 (5%)
Edema 0 2 (5%) 0
Dysphonia 1 (3%) 1 (2%) 3 (7%)
Diarrhea 0 2 (5%) 0
Oral candidiasis 3 (8%) 11 (26%) 17 (40%)
Coughing 2 (5%) 0 0
Pharyngitis 1 (3%) 3 (7%) 4 (9%)
Dry throat 0 2 (5%) 0
Pruritus 0 1 (2%) 2 (5%)
Only those events reported by more than 2 patients (or X5% of total) are indicated. The percentages (indicated in parentheses) are
based on the number of patients in each group.
Inhaled mometasone furoate reduces oral prednisone usage 635reported in more than 5% of patients included fatigue (6%),
arthralgia (11%), myalgia (5%), and musculoskeletal pain
(8%). There were no clinically relevant changes in vital signs,
physical examinations, EKGs, or clinical laboratory tests. At
endpoint for the open-label study, precosyntropin and
postcosyntropin serum cortisol levels were higher than at
screening (precosyntropin: 10.44, 7.22, 7.21 mg/dL and
postcosyntropin: 18.91, 13.38, 16.78 mg/dL for placebo,
MF-MDI 400 mg bid, and MF-MDI 800 mg bid, respectively).
The percentage of patients with morning plasma cortisol
concentrations of less than 5 mg/dL decreased from 67% (20/
30) at screening to 23% (7/30) on Week 52 of the open-label
study. The percentage of abnormal responders to cosyntro-
pin (postcosyntropin minus precosyntropin cortisol levels of
o7 mg/dL) decreased from 63% (19/30) at screening to 50%
(15/30) on Week 52 of the open-label study.Discussion
MF-MDI administered in dosages of 400 or 800 mg bid,
effectively reduced, or in a large number of cases,
completely eliminated the oral prednisone requirement in
patients with OCS-dependent severe persistent asthma. In
contrast, the OCS dose was increased in patients in the
placebo group who did not receive replacement ICS. These
results highlight how large an impact a stable regimen of ICS
use has on minimizing severe asthma symptoms and thus OCS
use. Interestingly, although most patients previously had
been treated with other ICS (the majority on high doses of
ﬂuticasone propionate), those treated with either dose of
MF-MDI during the study signiﬁcantly reduced their pre-
dnisone dose while showing clinically signiﬁcant improve-
ment in pulmonary function. Furthermore, signiﬁcant
improvement was also seen in patient symptoms compared
with placebo, the use of rescue medication (albuterol), and
the physician’s evaluation of response to therapy. At the 9-
month endpoint of an open-label extension using MF-MDI for
all patients, those previously treated with MF-MDI had
further reductions in prednisone requirements, and patientspreviously treated with placebo reduced their oral pre-
dnisone requirements.
OCS-sparing effects, with improvement in pulmonary and
other disease parameters, have been reported for MF
delivered by DPI,9 ﬂuticasone propionate6,8 and budesonide
(400 and 800 mg bid)7 in a signiﬁcant percentage of patients
with OCS-dependent severe persistent asthma. It is not
possible to directly compare the effects of each ICS on OCS-
sparing among these studies, since differences exist in
experimental design and study populations.9 For example,
the present study strictly enforced the titration of OCS dose
to the minimum effective dose needed to maintain control
prior to entry into the study. Also, most of the patients were
taking medium-to-high doses of ICS prior to the study, most
commonly high doses of ﬂuticasone propionate, and still
needed OCS. The lengths of the different studies also vary,
and longer study duration leads to greater reduction of the
OCS dose by ICS.9 The ﬁndings using MF-MDI are similar to
previous ﬁndings with MF using a DPI and a similar protocol.9
Both doses of MF-MDI bid showed signiﬁcant improvement
in most parameters examined compared with placebo.
There were no additional beneﬁts of the 800 mg bid dose
over the 400 mg bid dose. Although two asthma-speciﬁc
parameters, total score and psychosocial impact, in the MF-
MDI 800 mg bid group were signiﬁcant, the study was not
powered for HRQOL. The 400 mg bid dose of MF-MDI is likely
on the plateau of the dose-response curve for most
endpoints in these patients with severe persistent asthma.
Therefore, on the basis of the doses used in the present
study, MF-MDI 400 mg bid should be sufﬁcient in most
patients, while decreasing the possibility of systemic
exposure relative to the 800 mg bid dose of MF-MDI.
The plasma MF measurements suggest that only low levels
of systemic exposure to corticosteroids may occur with MF-
MDI. The proportion of patients in which detectable levels
were found was higher with MF-MDI 800 mg bid dosing. A
large proportion of patients in this study had abnormal HPA-
axis function at screening. Mean basal and cosyntropin-
stimulated plasma cortisol concentrations, which were low
before study randomization due to OCS use, increased in
both MF-MDI treated groups by the end of the double-blind
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J.P. Karpel et al.636study. Further increases were also seen by the end of the
open-label phase. The number of patients with abnormal
basal cortisol concentrations decreased by almost 3-fold by
the end of the open-label phase. The percentage of patients
taking MF-MDI with abnormal responses to cosyntropin
during the double-blind phase greatly decreased with MF-
MDI treatments by Week 12. In contrast, the percentage of
placebo patients with abnormal cosyntropin responses
increased by Week 12. These improvements in HPA-axis
function occurred as the dose of oral prednisone was
reduced by MF-MDI. A previous study of integrated (24-h
area under the curve) plasma cortisol levels found that
following 28 days of treatment, the degree of HPA-axis
suppression by MF-MDI 400 mg bid was comparable to
placebo.12 MF-MDI 800 mg bid did signiﬁcantly lower plasma
cortisol levels after 28 days by 22% relative to placebo.
Overall, these ﬁndings suggest that less systemic exposure
and fewer systemic effects should occur with the MF-MDI
400 mg bid than with the 800 mg bid dose.
Both doses of MF-MDI were well tolerated. The most
common treatment-related adverse events were local in
nature: oral candidiasis, pharyngitis, and dysphonia. The
incidence of oral candidiasis was high, although none of the
patients discontinued treatment because of this, and the
frequency decreased over time as observed in the open-
label phase. Results in a similar range have been observed in
OCS-reduction studies of other ICSs.6–8
In conclusion, MF-MDI administered twice daily is a well-
tolerated treatment that can eliminate or substantially
reduce oral prednisone requirements in patients with OCS-
dependent severe persistent asthma while substantially
improving pulmonary function and QoL.Acknowledgments
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